Sun Pharmaceutical Industries

SUNPHARMA · NSE · INR

₹1,801.00Change from previous close: −0.86%Absolute change: −₹15.60

Close · October 1, 2026

At a glance

Revenue growth
+11.19%
FY to Mar 2026 vs FY to Mar 2025
Net income growth
+5.04%
FY to Mar 2026 vs FY to Mar 2025
Net margin
19.6%
FY to Mar 2025: 20.8%

Financial data

Amounts in millions of INR; per-share values in INR; shares in millions.

Balance sheet · Annual
ItemFY to Mar 2026FY to Mar 2025FY to Mar 2024FY to Mar 2023FY to Mar 2022FY to Mar 2021FY to Mar 2020FY to Mar 2019FY to Mar 2018FY to Mar 2017
Total assets1,087,852921,006854,997807,436698,078676,667682,525646,938645,164614,102
Current assets638,912526,245434,750398,833348,646304,421316,542310,692316,359329,537
Cash and equivalents97,705102,68892,85746,23745,08362,73056,76670,62379,25486,628
Short-term investments44,33050,96653,71260,04144,69532,59248,59535,58360,51766,883
Receivables159,288136,007119,440119,117110,24398,905105,106100,63084,16484,976
Inventory120,585107,593102,949109,68392,39293,61882,69282,62468,80777,351
Net property, plant and equipment124,948112,703113,001113,537111,689111,715112,263109,382105,935100,601
Goodwill98,33189,39485,69083,58065,91362,87664,81559,55856,06755,362
Other intangible assets135,46290,20587,33093,26861,91856,60763,59563,53751,17648,803
Long-term investments37,89146,97764,41254,51749,59264,82452,45839,51830,52314,198
Current liabilities226,220181,942169,844199,070172,085161,456157,064173,396198,643178,870
Accounts payable73,33861,84356,53356,81544,89839,73735,83641,47947,66243,954
Long-term debt31325.213.30.02,2996,54717,77614,22916,68813,698
Total debt5,7704,9514,2939,2768,21814,23727,65521,43624,05631,769
Total liabilities249,055196,146183,737214,281187,417181,869191,278199,712223,181209,797
Total equity (incl. minority)838,797724,860671,259593,155510,661494,798491,247447,226421,983404,305
Retained earnings694,677614,525537,452472,009412,363401,887389,052369,130355,359342,036
Minority interest3,0972,67934,59233,20130,54930,17138,60233,13538,84237,909